A new study suggests that a blood test may not only help detect Alzheimer’s disease at an early stage, but could also estimate how many years remain before symptoms appear.

The findings were published in the journal Nature Medicine.

The research focuses on the biomarker p-tau217, a form of the tau protein associated with pathological brain changes characteristic of Alzheimer’s disease. Scientists found that levels of this protein begin to rise long before clinical symptoms such as memory loss and cognitive decline become noticeable.

Data analysis showed that changes in p-tau217 follow a relatively predictable pattern. Based on long-term observations, researchers developed a model linking biomarker levels with patient age, allowing them to estimate the time window until symptom onset. This goes beyond identifying risk and instead attempts to predict when the disease will manifest.

The progression rate, however, varies significantly. When pathological changes begin at a younger age, the disease tends to progress more slowly, sometimes taking years or even decades to develop. In contrast, when onset occurs later in life, the transition to symptoms is typically faster.

The study also highlights that Alzheimer’s disease begins long before it can be clinically diagnosed. This may explain why many current treatments show limited effectiveness, as substantial brain changes are already present by the time symptoms appear.

According to the authors, such tests could transform both diagnosis and treatment strategies. The ability to estimate disease timing in advance may enable earlier intervention and improve the selection of patients for clinical trials of new therapies.

However, the researchers emphasize that the method is not yet ready for widespread clinical use. It requires further validation in larger patient cohorts and standardization before it can be implemented in routine practice.